Tactiva Therapeutics LLC, a new biotech company spun off from Roswell Park Comprehensive Cancer Center, will create jobs as it develops some of the most promising concepts in the burgeoning field of cancer immunotherapy and accelerates the timeline for getting beneficial therapies to patients.

More than 1 in 4 adults and nearly 1 in 10 youth use tobacco, according to findings from the Population Assessment of Tobacco and Health (PATH) Study, published online ahead of print in the New England Journal of Medicine. The PATH Study, established in 2011 through collaboration between the National Institutes of Health’s National Institute on Drug Abuse and the U.S. Food and Drug Administration’s Center for Tobacco Products, is a uniquely large, nationally representative longitudinal study designed to examine tobacco use behaviors and health among the U.S. population over multiple years of follow-up. The PATH Study is being conducted by Westat of Rockville, Md., with Roswell Park Comprehensive Cancer Center as the scientific lead.

Metastasis, or spread of a tumor from the site of origin to additional organs, causes >90% of cancer-related deaths, but our understanding of the molecular mechanisms behind metastasis remains limited.

Roswell Park Cancer Institute faculty members are among the leaders who helped to plan the 2017 Gastrointestinal Cancer Symposium, a three-day specialized oncology meeting that continues through Jan. 21 in San Francisco, CA. Gastrointestinal cancers include cancers of the pancreas, small bowel, hepatobiliary tract, colon, rectum, esophagus and stomach.

New York Governor Andrew Cuomo’s plan to regulate and tax vapor products used in electronic cigarettes is an important step in protecting youth and nonusers from possible detrimental impacts, say experts from Roswell Park Comprehensive Cancer Center and Tobacco-Free Western New York (TFWNY).